Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Compuestos inhibidores de la enzima colesterol 24-hidroxilasa para el tratamiento del deterioro cognitivo asociado con la edad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150416002
Publicado:
27/08/2015
Caducidad:
26/08/2016
Resumen:
Un centro público de investigación y una universidad españoles han demostrado que el uso de compuestos de azole administrados por vía oral inhiben la enzima colesterol 24-hidroxilasa (Cyp46A) y son útiles en el tratamiento del deterioro cognitivo leve (pérdida de concentración y memoria) asociado con la edad. En comparación con los medicamentos convencionales, estos compuestos son más específicos en el cerebro y pueden emplearse en el tratamiento de personas mayores. Se buscan compañías farmacéuticas y biotecnológicas para desarrollar esta tecnología y establecer acuerdos de licencia.

Details

Tittle:
Inhibitor compounds of Cholesterol 24-hydroxylase enzyme for treating cognitive impairment associated with aging
Summary:
A Spanish public research organisation and a Spanish university have demonstrated that the use of Azole compounds, administered orally, inhibit the Cholesterol 24-hydroxylase enzyme (Cyp46A) being useful for the treatment of mild cognitive impairment (loss of concentration and memory) associated with aging. Pharma and biotech companies are sought to develop this technology via licensing agreement.
Description:
The worldwide increase in average life expectancy during the last half century has produced a high incidence of cognitive disorders related to aging (loss of concentration and memory). In many cases, the loss of cognitive capacities in elderly people could be an early sign of progression to Alzheimer´s disease.

Currently used drugs improve cognitive ability (nootropic): i.e. amphetamines, methylphenidate (Ritalin) and modafinil (Provigil) work at neurotransmitters level and not have any effect on old or senile people. Besides some of them are addictive drugs and cause emotional disorders and peripheral effects.

The tests performed by the researchers have shown that triazole derivatives, administered orally, act specifically on the enzyme of cholesterol turnover in the brain (24-hydroxylase (Cyp46A1)) preventing the degradation of the neuronal membrane cholesterol which occurs with aging.

We are looking for Pharmaceutical, Biopharmaceutical and/or Drug repositioning companies in the field of neurodegenerative, neurological and cognitive disorders interested in licensing agreement.
Advantages and Innovations:
- The azolic compounds are able to cross the blood brain barrier inhibiting the enzyme cholesterol 24-hydroxylase (Cyp46A1).
- These compounds are known and commonly used in clinical practice, without noticeable side effects.
- In comparison to conventional drugs these are more specific for the brain and can be used for the elderly people treatment.
- They can be used for mild cognitive impairment (MCI) which often precedes the onset of Alzheimer´s disease as well as treatment of cognitive deficits caused after by brain injury.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority established by a Spanish patent application.

Partner sought

Type and Role of Partner Sought:
Pharmaceutical, Biopharmaceutical or SME companies that develop drugs for the treatment related to neurodegenerative, neurological and cognitive disorders.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001010 Gerontología y geriatría
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos